FreeTheAI

Parabilis Medicines Begins Dose-Ranging Study of Zolucatetide in Familial Adenomatous Polyposis

MixedMedium impact
PBLS$26.85 −7.25%

Parabilis Medicines, Inc. (NASDAQ:PBLS) has initiated a dose-ranging clinical cohort evaluating its lead drug candidate, zolucatetide, in adults with familial adenomatous polyposis (FAP). The new patient group is part of an ongoing Phase 1/2 multicenter, open-label trial testing the drug across diseases driven by the Wnt/beta-catenin signaling pathway. The study focuses on patients with a documented APC mutation who have previously undergone a colectomy and have measurable duodenal polyp burden.

FAP is a rare genetic disorder that causes hundreds to thousands of precancerous polyps to form in the digestive tract, placing patients at severe risk of developing gastrointestinal cancer. Because no systemic treatments are currently approved for the condition, patients must rely on lifelong monitoring and repeated surgical procedures. Zolucatetide targets the underlying disease biology by directly inhibiting the beta-catenin:TCF interaction. Early clinical data from the trial showed noticeable reductions in duodenal polyp burden, including cases where patients moved from Spigelman Stage IV to near-normal or Stage II to Stage I, with a favorable safety profile.

Investors and clinicians can expect further clinical data from FAP patients in the trial during the first quarter of 2027. Parabilis is also planning a Phase 3 trial evaluating zolucatetide in desmoid tumors while advancing the candidate in other indications, including hepatocellular carcinoma. Shares of Parabilis Medicines fell 7.25% to $26.85 on the day of the announcement.

Key points

  • Parabilis Medicines started a dose-ranging Phase 1/2 cohort testing zolucatetide in adults with familial adenomatous polyposis.
  • Zolucatetide directly inhibits the beta-catenin:TCF interaction to address the root genetic driver of polyp formation in FAP.
  • Early clinical data showed significant reductions in duodenal polyp burden in FAP patients, along with a favorable safety profile.
  • Additional Phase 1/2 trial data for FAP patients is scheduled for disclosure in the first quarter of 2027.
  • Shares of Parabilis Medicines (NASDAQ:PBLS) fell 7.25% to $26.85 on the day of the announcement.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is zolucatetide and how does it work?

Zolucatetide is an investigational peptide developed by Parabilis Medicines that directly inhibits the beta-catenin:TCF interaction, blocking the genetic pathway that drives precancerous polyps and tumors.

What is familial adenomatous polyposis?

Familial adenomatous polyposis (FAP) is a genetic disease caused by mutations in the APC gene. It leads to hundreds or thousands of precancerous gastrointestinal polyps, creating a high risk of cancer without surgery or management.

When will Parabilis Medicines release more clinical data for zolucatetide?

Parabilis Medicines expects to report additional data from patients with FAP in the ongoing Phase 1/2 trial during the first quarter of 2027.